World Trade Flash

Aktis Oncology targets up to $945 million valuation in upsized US IPO

Aktis Oncology targets up to $945 million valuation in upsized US IPO

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, underscoring strong investor demand for 2026's...

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
INFINITY AI
Instagram Meta X LinkedIn Whatsapp